Effect of pitavastatin treatment on ApoB-48 and Lp-PLA2 in patients with metabolic syndrome: Substudy of prospective comparative clinical study evaluating the efficacy and safety of pitavastatin in patients with metabolic syndrome
- Authors
- Lee, H.-S.; Jung, C.H.; Kim, S.R.; Jang, H.C.; Park, C.-Y.; Choi, S.H.; Lim, S.; Seo, J.A.; Noh, J.H.; Mok, J.O.; Lee, K.Y.; Park, J.S.; Kim, D.J.; Lee, C.B.
- Issue Date
- Mar-2016
- Publisher
- Korean Endocrine Society
- Keywords
- Apolipoprotein B-48; Lp-PLA2; Metabolic syndrome; Pitavastatin
- Citation
- Endocrinology and Metabolism, v.31, no.1, pp.120 - 126
- Journal Title
- Endocrinology and Metabolism
- Volume
- 31
- Number
- 1
- Start Page
- 120
- End Page
- 126
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8808
- DOI
- 10.3803/EnM.2016.31.1.120
- ISSN
- 2093-596X
- Abstract
- Background: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study. Methods: We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks. Results: Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P ≤ 0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year. Conclusion: Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels. © 2016 Korean Endocrine Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8808)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.